Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies

References

• Alsarra IA, Hamed AY, Alanazi FK, El Maghraby GM. (2010). Vesicular systems for intranasal drug delivery. New York: Springer-Verlag
   Google Scholar
• Alyaudtin RN, Reichel A, Lobenberg R, et al. (2001). Interaction of poly(butylcyanoacrylate) nanoparticles with the blood–brain barrier in vivo and in vitro. J Drug Target 9:209–21
   PubMed Web of Science ®Google Scholar
• Arumugam K, Subramanian GS, Mallayasamy SR, et al. (2008). A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 58:287–97
   PubMed Web of Science ®Google Scholar
• Association AS. (2012). 2012 Alzheimer’s disease facts and figures. Alzheimer's Dement 8:131–68
   PubMed Web of Science ®Google Scholar
• Avgoustakis K, Beletsi A, Panagi Z, et al. (2002). PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 79:123–35
   PubMed Web of Science ®Google Scholar
• Bancroft JD, Gamble M. (2008). Theory and practice of histological techniques. Philadelphia: Elsevier Health Sciences
   Google Scholar
• Borchard G, Audus KL, Shi F, Kreuter J. (1994). Uptake of surfactant-coated poly (methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 110:29–35
   Web of Science ®Google Scholar
• Braak H, Braak E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–59
   PubMed Web of Science ®Google Scholar
• Brgles M, Jurasin D, Sikiric MD, et al. (2008). Entrapment of ovalbumin into liposomes-factors affecting entrapment efficiency, liposome size, and zeta potential. J Liposome Res 18:235–48
   PubMed Web of Science ®Google Scholar
• Burgess D, Wright J. (2012). Long acting injections and implants, advances in delivery science and technology. Berlin, Germany: Springer
   Google Scholar
• Capone R, Quiroz FG, Prangkio P, et al. (2009). Amyloid-beta-induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy. Neurotox Res 16:1–13
   PubMed Web of Science ®Google Scholar
• Chen WL, Yuan ZQ, Liu Y, et al. (2016). Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro. Int J Nanomed 11:325–36
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, et al. (2007). Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24
   PubMed Web of Science ®Google Scholar
• Degim Z, Mutlu NB, Yilmaz S, et al. (2010). Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie 65:32–40
   PubMed Web of Science ®Google Scholar
• Du G, Gao Y, Nie S, Pan W. (2006). The permeation of nalmefene hydrochloride across different regions of ovine nasal mucosa. Chem Pharm Bull (Tokyo) 54:1722–4
   PubMed Web of Science ®Google Scholar
• El-Helaly SN, Elbary AA, Kassem MA, El-Nabarawi MA. (2014). Design, development and statistical evaluation of positively charged rivastigmine liposomes. Inventi Rapid: Pharm Tech 4:1–8
   Google Scholar
• El-Kosasy AM, Salem MY, El-Bardicy MG, El-Rahman MK. (2008). Miniaturized membrane sensors for the determination of rivastigmine hydrogen tartrate. Chem Pharm Bull (Tokyo) 56:753–7
   PubMed Web of Science ®Google Scholar
• Fazil M, Md S, Haque S, et al. (2012). Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 47:6–15
   PubMed Web of Science ®Google Scholar
• Francis PT, Palmer AM, Snape M, Wilcock GK. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–47
   PubMed Web of Science ®Google Scholar
• Jesorka A, Orwar O. (2008). Liposomes: technologies and analytical applications. Annu Rev Anal Chem (Palo Alto, CA) 1:801–32
   PubMed Web of Science ®Google Scholar
• Johnson PH, Quay SC. (2005). Advances in nasal drug delivery through tight junction technology. Expert Opin Drug Deliv 2:281–98
   PubMedGoogle Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. (1995). Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171–4
   PubMed Web of Science ®Google Scholar
• Kurz A, Farlow M, Lefevre G. (2009). Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 63:799–805
   PubMed Web of Science ®Google Scholar
• Law SL, Huang KJ, Chou HY. (2001). Preparation of desmopressin-containing liposomes for intranasal delivery. J Control Release 70:375–82
   PubMed Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. (2012). PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 13:105–19
   PubMed Web of Science ®Google Scholar
• Moore J, Flanner H. (1996). Mathematical comparison of curves with an emphasis on in-vitro dissolution profiles. Pharm Technol 20:64–74
   Google Scholar
• Moretti R, Torre P, Vilotti C, et al. (2007). Rivastigmine and Parkinson dementia complex. Expert Opin Pharmacother 8:817–29
   PubMed Web of Science ®Google Scholar
• Rodgers AB. (2011). Alzheimer's disease unraveling mystery. Available at: http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-unraveling-mystery/preface
   Google Scholar
• Romeo VD, de Meireles JC, Gries WJ, et al. (1998). Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv Drug Deliv Rev 29:117–33
   PubMed Web of Science ®Google Scholar
• Rovira-Bru M, Thompson DH, Szleifer I. (2002). Size and structure of spontaneously forming liposomes in lipid/PEG-lipid mixtures. Biophys J 83:2419–39
   PubMed Web of Science ®Google Scholar
• Schnyder A, Huwyler J. (2005). Drug transport to brain with targeted liposomes. NeuroRx 2:99–107
   PubMedGoogle Scholar
• Schroeder U, Sommerfeld PSabel BA. (1998). Efficacy of oral dalargin-loaded nanoparticle delivery across the blood–brain barrier. Peptides 19:777–80
   PubMed Web of Science ®Google Scholar
• Seju U, Kumar A, Sawant KK. (2011). Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 7:4169–76
   PubMed Web of Science ®Google Scholar
• Siepmann J, Siegel RA, Rathbone MJ. (2011). Fundamentals and applications of controlled release drug delivery. Boston, MA: Springer Science & Business Media
   Google Scholar
• Squire LR, Zola-Morgan S. (1991). The medial temporal lobe memory system. Science 253:1380–6
   PubMed Web of Science ®Google Scholar
• Szoka F, Papahadjopoulos D. (1978). Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci 75:4194–8
   PubMed Web of Science ®Google Scholar
• Tas C, Ozkan CK, Savaser A, et al. (2006). Nasal absorption of metoclopramide from different Carbopol 981 based formulations: in vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm 64:246–54
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481–96
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shahiwala A, Marathe S, Misra A. (2005). Intranasal drug delivery for brain targeting. Curr Drug Deliv 2:165–75
   PubMedGoogle Scholar
• Were LM, Bruce BD, Davidson PM, Weiss J. (2003). Size, stability, and entrapment efficiency of phospholipid nanocapsules containing polypeptide antimicrobials. J Agric Food Chem 51:8073–9
   PubMed Web of Science ®Google Scholar
• Woodbury DJ, Richardson ES, Grigg AW, et al. (2006). Reducing liposome size with ultrasound: bimodal size distributions. J Liposome Res 16:57–80
   PubMed Web of Science ®Google Scholar
• Woodle MC. (1995). Sterically stabilized liposome therapeutics. Adv Drug Deliv Rev 16:249–65
   Web of Science ®Google Scholar
• Xiang J, Fang X, Li X. (2002). Transbuccal delivery of 2′,3′-dideoxycytidine: in vitro permeation study and histological investigation. Int J Pharm 231:57–66
   PubMed Web of Science ®Google Scholar
• Yadav A, Murthy M, Shete AS, Sakhare S. (2011). Stability aspects of liposomes. Indian J Pharm Educ Res 45:402–13
   Web of Science ®Google Scholar
• Yamada T. (2004). The potential of the nasal mucosa route for emergency drug administration via a high-pressure needleless injection system. Anesth Prog 51:56–61
   PubMedGoogle Scholar
• Yang T, Choi MK, Cui FD, et al. (2007a). Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169–77
   PubMed Web of Science ®Google Scholar
• Yang T, Cui FD, Choi MK, et al. (2007b). Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 338:317–26
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Wang ZZ, Wu K, Qi XR. (2011). Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration. Yao Xue Xue Bao 46:859–63
   PubMedGoogle Scholar
• Yang ZZ, Zhang YQ, Wang ZZ, et al. (2013). Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 452:344–54
   PubMed Web of Science ®Google Scholar